Cargando…

Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens

BACKGROUND: Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) offers persons living with HIV a potent new treatment option. Recently, local HIV clinicians noted weight gain in patients who switched from daily, fixed-dose efavirenz/tenofovir disoproxil fumarate/emtricitab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Norwood, Jamison, Turner, Megan, Bofill, Carmen, Jenkins, Cathy, Bebawy, Sally, Rebeiro, Peter, Hulgan, Todd, Raffanti, Stephen, Haas, David, Sterling, Timothy R, Koethe, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631481/ http://dx.doi.org/10.1093/ofid/ofx163.1094

Ejemplares similares

1605 Active Marijuana Use Was Not Associated with Changes in Body Mass Index or CD4 T-Cell Countsi n HIV-Infected Patients
por: Lee, James, et al.
Publicado: (2014)

Association Between Patient Portal Access and Viral Suppression Among People Living with HIV in a Large Southeastern Clinical Cohort
por: Scott, Sarah, et al.
Publicado: (2017)

Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
por: Pohlman, F Will, et al.
Publicado: (2021)

LB9. The Effect of Initiating Integrase Inhibitor-based vs. Non-Nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care
por: Rebeiro, Peter F, et al.
Publicado: (2019)

1985. A Prospective, Randomized Trial to Assess a Protease Inhibitor–based Regimen Switch Strategy to Manage Integrase Inhibitor–related Weight Gain
por: Short, William R, et al.
Publicado: (2023)

334. Weight Change Associated with Antiretroviral Therapy Switch to Integrase Strand Transfer Inhibitor-Based Regimens
por: Saber, Saghar, et al.
Publicado: (2019)

Weight Gain in Incarcerated Individuals Living With HIV After Switching to Integrase Strand Inhibitor-Based Therapy
por: Goldberg, Rachel N., et al.
Publicado: (2021)

Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada
por: Bourgi, Kassem, et al.
Publicado: (2020)

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens
por: Kim, Jin, et al.
Publicado: (2022)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Single-tablet regimen is associated with reduced efavirenz withdrawal in antiretroviral naïve or switching for simplification HIV-infected patients
por: Fabbiani, M, et al.
Publicado: (2012)

1568 Use of the Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in a Predominantly African-American HIV Infected Population
por: Bryant, Paul, et al.
Publicado: (2014)

952. Weight-Gain in Treatment Naive Newly Diagnosed HIV-Infected Persons After Initiation on Integrase Strand Inhibitor Based Treatment Regimens
por: Szep, Zsofia, et al.
Publicado: (2020)

Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal
por: Canestri, Anna, et al.
Publicado: (2007)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus
por: Desmonde, Sophie, et al.
Publicado: (2019)

Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen
por: Ferreira, Roux-Cil, et al.
Publicado: (2023)

Antiretroviral Therapy Initiation Before, During, or After Pregnancy in HIV-1-Infected Women: Maternal Virologic, Immunologic, and Clinical Response
por: Melekhin, Vlada V., et al.
Publicado: (2009)

1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
por: Cutshaw, Melissa Klein, et al.
Publicado: (2023)

T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens
por: da Silva, Tatiana P., et al.
Publicado: (2013)

A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings
por: Erlandson, Kristine M., et al.
Publicado: (2015)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
por: da Silva, Gabriella Jomara, et al.
Publicado: (2023)

538. Integrase Inhibitor-Based HAART Is Associated with Greater BMI Gains in Blacks, Hispanics, and Women
por: Bedimo, Roger, et al.
Publicado: (2018)

Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials
por: Shu, Yuanlu, et al.
Publicado: (2021)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
por: Twimukye, Adelline, et al.
Publicado: (2021)

Efavirenz Conceptions and Regimen Management in a Prospective Cohort of Women on Antiretroviral Therapy
por: Schwartz, Sheree, et al.
Publicado: (2012)

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2018)

1540 New Faces of HIV Infection: Differences between Younger and Older Persons Presenting for HIV Care in Nashville, Tennessee
por: Smith, Kaylin, et al.
Publicado: (2014)

Urinary Eicosanoid Metabolites in HIV-Infected Women with Central Obesity Switching to Raltegravir: An Analysis from the Women, Integrase, and Fat Accumulation Trial
por: Hulgan, Todd, et al.
Publicado: (2014)

Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America
por: Caro-Vega, Yanink, et al.
Publicado: (2018)

Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
por: Peng, Yongquan, et al.
Publicado: (2023)

Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
por: Plum, Pierre-Emmanuel, et al.
Publicado: (2021)

332. Exploring the Prevalence and Characteristics of Weight Gain and other Metabolic Changes in Patients with HIV Infection Switching to Integrase Inhibitor Containing ART
por: Zimmerman, Matty, et al.
Publicado: (2019)

Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGE(h)IV cohort participants
por: Verboeket, Sebastiaan O., et al.
Publicado: (2021)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_96liarmoo05skp0hbfqs8odsd0